Jiangsu Recbio Technology's (HKG:2179) application for a clinical trial of its HPV 9-valent vaccine REC604c has been accepted by China's National Medical Products Administration, a Wednesday bourse filing said.
REC604c is a novel recombinant HPV 9-valent vaccine that the vaccine maker plans to develop for the male and upgraded markets.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.